Eli Lilly and Company (NYSE: LLY) shares staged a sharp rally on Thursday, jumping nearly 10% to around $935.40, up $84.18 in intraday trading, after the company delivered a first-quarter report that showed just how powerful its obesity and diabetes drug franchise has become.
The move was driven by stronger-than-expected demand for Eli Lilly’s GLP-1 treatments, led by Mounjaro and Zepbound. Revenue for the quarter rose 56% year over year to $19.7 billion, a pace of growth rarely seen at this scale among large pharmaceutical companies.
For investors, the report offered a clear message: even with pricing pressure in the U.S. market, patient demand for GLP-1 drugs remains strong enough to keep Lilly’s growth engine running at high speed.
Eli Lilly’s GLP-1 business becomes the main growth driver
The biggest reason behind the rally was the performance of Lilly’s GLP-1 portfolio. Mounjaro, the company’s diabetes treatment that has also seen strong weight-management demand, generated $8.66 billion in quarterly revenue, up 125% from a year earlier.
Zepbound, Lilly’s obesity drug, brought in $4.16 billion, rising 80% year over year. Together, the two drugs produced roughly $12.82 billion in sales, meaning GLP-1 treatments accounted for about two-thirds of Eli Lilly’s total quarterly revenue.
That level of concentration highlights both the opportunity and the risk for Eli Lilly (LLY). On one hand, the company is sitting at the center of one of the fastest-growing areas in healthcare. On the other hand, investors will keep watching whether growth can remain strong as competitors expand supply and insurers push for lower prices.
The broader GLP-1 category has grown quickly because these drugs are being used to treat type 2 diabetes, obesity, and other metabolic conditions. The U.S. Food and Drug Administration remains an important source for drug approvals, safety updates, and regulatory information tied to this fast-moving market.
Lower prices did not stop revenue growth
One of the more important details in the quarter was that Lilly still delivered major revenue growth despite lower realized prices for some GLP-1 drugs in the U.S. That suggests prescription volumes and demand growth were strong enough to offset pricing pressure.
This matters because pricing has been one of the biggest concerns weighing on healthcare stocks tied to obesity drugs. Investors have worried that insurers, pharmacy benefit managers, and government programs could pressure margins over time. Lilly’s latest quarter showed that volume growth remains powerful for now.
Read More
The company also received a fresh boost from the approval of Foundayo, its oral GLP-1 pill. According to Lilly CEO David Ricks, the drug is notable because it can be taken any time of day without food or water restrictions. That convenience could help Lilly reach patients who prefer pills over injections.
An oral GLP-1 option could become a major advantage if adoption broadens. Injectable drugs have driven the early boom, but pill-based treatments may expand the market further by making therapy easier for more patients to start and stay on.
LLY stock rebounds, but 2026 has still been uneven
Thursday’s jump gave Eli Lilly stock a strong short-term lift, but the shares are still down roughly 13% year to date. That decline reflects earlier concerns over valuation, competition, and the possibility that pricing pressure could slow profit growth.
Competition remains intense. Novo Nordisk (NYSE: NVO), maker of Ozempic and Wegovy, continues to be Lilly’s closest rival in the GLP-1 market. Both companies are racing to expand manufacturing, improve drug delivery, and develop next-generation treatments.
Still, Lilly’s latest numbers strengthened the argument that demand remains far from saturated. A quarterly revenue base of $19.7 billion, with GLP-1 drugs contributing the majority of sales, gives the company a powerful earnings platform if it can keep expanding supply.
For readers following similar market moves, Swikblog’s finance and stock market coverage tracks major earnings reactions, stock price moves, and sector trends across U.S. markets.
What investors should watch next
The next phase of the Eli Lilly story will depend on three key factors: supply, pricing, and competition. Demand for GLP-1 drugs remains extremely strong, but Lilly must continue scaling production to meet prescriptions without creating shortages.
Pricing will also stay in focus. If lower prices become more widespread, Lilly will need continued volume growth to protect revenue momentum. The first-quarter report suggests that demand is currently strong enough to absorb that pressure, but investors will want confirmation in coming quarters.
The third factor is innovation. Foundayo gives Lilly a new growth angle in oral GLP-1 treatment, while its pipeline could help defend market share as Novo Nordisk and other drugmakers push further into obesity and metabolic care.
For now, Eli Lilly’s latest results show a company benefiting from one of the strongest demand cycles in global pharmaceuticals. With Mounjaro sales up 125%, Zepbound revenue rising 80%, and total revenue climbing 56%, the stock’s nearly 10% rally reflects investor confidence that the GLP-1 boom still has room to run.
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
